Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Valneva (08/09/2020)

13.09.2020

Valneva: Valneva SE, a French/Austrian specialty vaccine company focused on prevention of diseases with major unmet needs, announced the initiation of a pivotal Phase 3 clinical trial for its differentiated, single-shot chikungunya vaccine candidate VLA1553.  The sponsor of the first chikungunya vaccine Biologics License Application (BLA) to be approved in the U.S. will be eligible to receive a Priority Review Voucher (PRV). The study, called VLA1553-301, is a double-blinded, placebo-controlled, multi-center study in approximately 4,000 healthy adults aged 18 or above, conducted in the U.S. Participants will be randomized into two study groups to receive either vaccine or placebo. The primary endpoint will be to demonstrate safety and immunogenicity 28 days after a single-shot vaccination with VLA1553. A subset of participants will be tested for sero-protection based on an immunological surrogate (under the Accelerated Approval pathway). Participants will be followed for a total of six months. The total duration of the study is expected to be nine months and the outcome, if positive, shall provide the basis for licensure of the vaccine.  Wolfgang Bender, Chief Medical Officer of Valneva, commented, “We are the first company worldwide to advance a chikungunya vaccine candidate into Phase 3. We believe that VLA1553 has best-in class potential. Developing a vaccine against chikungunya is critical as the virus represents a major public health threat and there are currently no preventive vaccines or effective treatments available. We would like to thank our employees who are making this trial possible despite the ongoing COVID-19 pandemic.” The target population segments are travelers, military personnel and individuals at risk living in endemic regions. The global market for vaccines against chikungunya is estimated to exceed USD 500 mn annually, including a traveler vaccine market potential of around USD 250 mn.
Valneva: weekly performance: 8.17%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (08/09/2020)


Partners









latest 21st Austria

21st Austria weekly - Valneva (08/09/2020)


13.09.2020


Valneva: Valneva SE, a French/Austrian specialty vaccine company focused on prevention of diseases with major unmet needs, announced the initiation of a pivotal Phase 3 clinical trial for its differentiated, single-shot chikungunya vaccine candidate VLA1553.  The sponsor of the first chikungunya vaccine Biologics License Application (BLA) to be approved in the U.S. will be eligible to receive a Priority Review Voucher (PRV). The study, called VLA1553-301, is a double-blinded, placebo-controlled, multi-center study in approximately 4,000 healthy adults aged 18 or above, conducted in the U.S. Participants will be randomized into two study groups to receive either vaccine or placebo. The primary endpoint will be to demonstrate safety and immunogenicity 28 days after a single-shot vaccination with VLA1553. A subset of participants will be tested for sero-protection based on an immunological surrogate (under the Accelerated Approval pathway). Participants will be followed for a total of six months. The total duration of the study is expected to be nine months and the outcome, if positive, shall provide the basis for licensure of the vaccine.  Wolfgang Bender, Chief Medical Officer of Valneva, commented, “We are the first company worldwide to advance a chikungunya vaccine candidate into Phase 3. We believe that VLA1553 has best-in class potential. Developing a vaccine against chikungunya is critical as the virus represents a major public health threat and there are currently no preventive vaccines or effective treatments available. We would like to thank our employees who are making this trial possible despite the ongoing COVID-19 pandemic.” The target population segments are travelers, military personnel and individuals at risk living in endemic regions. The global market for vaccines against chikungunya is estimated to exceed USD 500 mn annually, including a traveler vaccine market potential of around USD 250 mn.
Valneva: weekly performance: 8.17%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (08/09/2020)




 

Bildnachweis

Aktien auf dem Radar:VIG, Semperit, Mayr-Melnhof, Warimpex, Palfinger, Zumtobel, Addiko Bank, Verbund, AMS, Strabag, Agrana, Kapsch TrafficCom, Josef Manner & Comp. AG, OMV, Polytec, Marinomed Biotech.


Random Partner

FACC
Die FACC ist führend in der Entwicklung und Produktion von Komponenten und Systemen aus Composite-Materialien. Die FACC Leichtbaulösungen sorgen in Verkehrs-, Fracht-, Businessflugzeugen und Hubschraubern für Sicherheit und Gewichtsersparnis, aber auch Schallreduktion. Zu den Kunden zählen u.a. wichtige Flugzeug- und Triebwerkshersteller.

>> Besuchen Sie 56 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten